[1].  Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol 2023;212:115545. https://doi.org/10.1016/J.BCP.2023.115545.

[2].  Zhu M, Yu M, Meng Y, Yang J, Wang X, LI L, et al. HER3 receptor and its role in the therapeutic management of metastatic breast cancer. J Transl Med 2024;22:665. https://doi.org/10.1186/S12967-024-05445-8.

[3].  Sabit H, Adel A, Abdelfattah MM, Ramadan RM, Nazih M, Abdel-Ghany S, et al. The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities. Cancer Lett 2025;628:217865.https://doi.org/10.1016/J.CANLET.2025.217865.

[4].  Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression. Front Oncol 2020;10:397. https://doi.org/10.3389/FONC.2020.00397.

[5].  Lee JS, Yost SE, Yuan Y. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. Cancers (Basel) 2020;12:1404.https://doi.org/10.3390/CANCERS12061404.

[6].  Raman R, Debata S, Govindarajan T, Kumar P. Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements. Cancer Med 2025;14:e70803. https://doi.org/10.1002/CAM4.70803.

[7].  Bili Newman A, Damodaran S, Meric-Bernstam F. Antibody-drug conjugates in breast cancer: Progress and future directions. Cell Rep Med 2026;7:102742. https://doi.org/10.1016/J.XCRM.2026.102742.

[8].  Sorrentino C, Ciummo SL, Fieni C, Di Carlo E. Nanomedicine for cancer patient‐centered care. MedComm (Beijing) 2024;5:e767. https://doi.org/10.1002/MCO2.767.

[9].  Jayaraj S, Jayaprakash N, Devaraji M, Murugavel S, Robinson AX, Murugesan L. Nanocarrier-based strategies for advanced cancer drug delivery and therapeutics: Design principles, biological interactions, and clinical potential. Nano Trends 2026;14:100203. https://doi.org/10.1016/J.NWNANO.2026.100203.

[10].       Cheng H, Liao J, Ma Y, Sarwar MT, Yang H. Advances in targeted therapy for tumor with nanocarriers: A review. Mater Today Bio 2025;31:101583.https://doi.org/10.1016/J.MTBIO.2025.101583.

[11].       Puluhulawa LE, Joni IM, Elamin KM, Mohammed AFA, Muchtaridi M, Wathoni N. Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy. Polymers (Basel) 2022;14:3410. https://doi.org/10.3390/POLYM14163410.

[12].       Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol 2020;9:36. https://doi.org/10.1186/S40164-020-00192-0.

[13].       Al Jayoush AR, Haider M, Khan SA, Hussain Z. Hyaluronic acid-functionalized nanomedicines for CD44-receptors-mediated targeted cancer therapy: A review of selective targetability and biodistribution to tumor microenvironment. Int J Biol Macromol 2025;308. https://doi.org/10.1016/J.IJBIOMAC.2025.142486.

[14].       Machado V, Morais M, Medeiros R. Hyaluronic Acid-Based Nanomaterials Applied to Cancer: Where Are We Now? Pharmaceutics 2022;14:2092. https://doi.org/10.3390/PHARMACEUTICS14102092.

[15].       Faya M, Za FA, Ballal AMA, Nwabuife JC, Serumula WS, Mamello ·, et al. Application of Hyaluronic Acid in Enhancing the Efficacy and Safety of Paclitaxel Nanoformulations for Cancer Treatment: A Recent Review. BioNanoScience 2026 16:7 2026;16:442-. https://doi.org/10.1007/S12668-026-02653-Y.

[16].       Kawaguchi M, Dashzeveg N, Cao Y, Jia Y, Liu X, Shen Y, et al. Extracellular Domains I and II of cell-surface glycoprotein CD44 mediate its trans-homophilic dimerization and tumor cluster aggregation. J Biol Chem 2020;295:2640. https://doi.org/10.1074/JBC.RA119.010252.

[17].       Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 2018;11:64. https://doi.org/10.1186/S13045-018-0605-5.

[18].       Xu H, Tian Y, Yuan X, Liu Y, Wu H, Liu Q, et al. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. Onco Targets Ther 2016;9:431. https://doi.org/10.2147/OTT.S97192.

[19].       Jordan AR, Racine RR, Hennig MJP, Lokeshwar VB. The Role of CD44 in Disease Pathophysiology and Targeted Treatment. Front Immunol 2015;6:182. https://doi.org/10.3389/FIMMU.2015.00182.

[20].       Mesrati MH, Syafruddin SE, Mohtar MA, Syahir A. CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules 2021;11:1850. https://doi.org/10.3390/BIOM11121850.

[21].       Marin JJG, Asensio M, Álvarez-Fernández L, Hortelano-Hernandez N, Delgado-Calvo K, Marijuan RP, et al. Impact of CD44 alternative splicing on the response to anticancer drugs. Biochem Pharmacol 2026;251:118111. https://doi.org/10.1016/J.BCP.2026.118111.

[22].       Giraud J, Seeneevassen L, Rousseau B, Bouriez D, Sifré E, Giese A, et al. CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma. Gastric Cancer 2022;26:234. https://doi.org/10.1007/S10120-022-01357-Y.

[23].       Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Experimental Hematology & Oncology 2020 9:1 2020;9:36-. https://doi.org/10.1186/S40164-020-00192-0.

[24].       Gałecki S, Gdowicz-Kłosok A, Deja R, Masłyk B, Giglok M, Suwiński R, et al. Common Variants in Osteopontin and CD44 Genes as Predictors of Treatment Outcome in Radiotherapy and Chemoradiotherapy for Non-Small Cell Lung Cancer. Cells 2023;12:2721. https://doi.org/10.3390/CELLS12232721/S1.

[25].       Wang Z, Zhao K, Hackert T, Zöller M. CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Front Cell Dev Biol 2018;6:97. https://doi.org/10.3389/FCELL.2018.00097.

[26].       Xu Y, Bai Z, Lan T, Fu C, Cheng P. CD44 and its implication in neoplastic diseases. MedComm (Beijing) 2024;5:e554. https://doi.org/10.1002/MCO2.554

[27].       Mosoane B, McCabe M, Jackson BS, Dlamini Z. CD44 Variant Expression in Follicular Cell-Derived Thyroid Cancers: Implications for Overcoming Multidrug Resistance. Molecules 2025, Vol 30, Page 1899 2025;30:1899. https://doi.org/10.3390/MOLECULES30091899.

[28].       Kobayashi H, Imanaka S, Shigetomi H. Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis. Oncol Lett 2022;23:80. https://doi.org/10.3892/OL.2022.13200.

[29].       Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc- and Thereby Promotes Tumor Growth. Cancer Cell 2011;19:387–400. https://doi.org/10.1016/J.CCR.2011.01.038.

[30].       Chen J, Ouyang J, Chen Q, Deng C, Meng F, Zhang J, et al. EGFR and CD44 Dual-Targeted Multifunctional Hyaluronic Acid Nanogels Boost Protein Delivery to Ovarian and Breast Cancers In Vitro and In Vivo. ACS Appl Mater Interfaces 2017;9:24140–7. https://doi.org/10.1021/ACSAMI.7B06879.

[31].       Wang Z, Zhao K, Hackert T, Zöller M. CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression. Front Cell Dev Biol 2018;6:97. https://doi.org/10.3389/FCELL.2018.00097.

[32].       McFarlane S, McFarlane C, Montgomery N, Hill A, Waugh DJJ. CD44-mediated activation of α5β1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and Fibronectin-enriched matrices. Oncotarget 2015;6:36762. https://doi.org/10.18632/ONCOTARGET.5461.

[33].       Hirao M, Sato N, Kondo T, Yonemura S, Monden M, Sasaki T, et al. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol 1996;135:37. https://doi.org/10.1083/JCB.135.1.37.

[34].       Bourguignon LYW. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008;18:251. https://doi.org/10.1016/J.SEMCANCER.2008.03.007.

[35].       Amabebe E, Ogidi H, Anumba DO. Matrix metalloproteinase-induced cervical extracellular matrix remodelling in pregnancy and cervical cancer. Reproduction & Fertility 2022;3:R177. https://doi.org/10.1530/RAF-22-0015.

[36].       Zou W, Yang Y, Zheng R, Wang Z, Zeng H, Chen Z, et al. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer. Int J Clin Exp Pathol 2020;13:1008.

[37].       He L, Wick N, Germans SK, Peng Y. The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:6209. https://doi.org/10.3390/CANCERS13246209.

[38].       Lee H, Kim B, Park J, Park S, Yoo G, Yum S, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduction and Targeted Therapy 2025 10:1 2025;10:248-. https://doi.org/10.1038/s41392-025-02360-2.

[39].       Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int 2018;2018:5416923. https://doi.org/10.1155/2018/5416923.

[40].       Wu X, Que H, Li Q, Wei X. Wnt/β-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol Cancer 2025;24:171. https://doi.org/10.1186/S12943-025-02363-1.

[41].       Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Experimental Hematology & Oncology 2020 9:1 2020;9:36-. https://doi.org/10.1186/S40164-020-00192-0.

[42].       Qiao Y, Mao H, Nie J, Liu M, Lou Q, Gao P, et al. Multidrug resistance in cancer: current understandings and future perspective. Molecular Biomedicine 2026 7:1 2026;7:98-. https://doi.org/10.1186/S43556-026-00502-8.

[43].       Graciela CQ, José Juan EC, Gieraldin CL, Xóchitl Alejandra PM, Gabriel AÁ. Hyaluronic Acid—Extraction Methods, Sources and Applications. Polymers (Basel) 2023;15:3473. https://doi.org/10.3390/POLYM15163473.

[44].       Jarmila P, Veronika M, Peter M. Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles. Int J Pharm X 2024;8:100281. https://doi.org/10.1016/J.IJPX.2024.100281.

[45].       Chaudhry GES, Akim A, Zafar MN, Safdar N, Sung YY, Muhammad TST. Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics. Adv Pharm Bull 2020;11:426. https://doi.org/10.34172/APB.2021.050.

[46].       Luo Z, Dai Y, Gao H. Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B 2019;9:1099–112. https://doi.org/10.1016/J.APSB.2019.06.004.

[47].       Lee BM, Park SJ, Noh I, Kim CH. The effects of the molecular weights of hyaluronic acid on the immune responses. Biomater Res 2021;25:27. https://doi.org/10.1186/S40824-021-00228-4.

[48].       Chrostek, L., & Cylwik, B. (2025). Hyaluronic Acid in Immune Response. Biomolecules, 15(7), 1008. https://doi.org/10.3390/biom15071008.

[49].       Luo Z, Dai Y, Gao H. Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B 2019;9:1099. https://doi.org/10.1016/J.APSB.2019.06.004.

[50].       Bokatyi AN, Dubashynskaya N V., Skorik YA. Chemical modification of hyaluronic acid as a strategy for the development of advanced drug delivery systems. Carbohydr Polym 2024;337:122145. https://doi.org/10.1016/J.CARBPOL.2024.122145.

[51].       Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer 2023;22:169. https://doi.org/10.1186/S12943-023-01865-0.

[52].       Marin JJG, Asensio M, Álvarez-Fernández L, Hortelano-Hernandez N, Delgado-Calvo K, Marijuan RP, et al. Impact of CD44 alternative splicing on the response to anticancer drugs. Biochem Pharmacol 2026;251:118111. https://doi.org/10.1016/J.BCP.2026.118111.

[53].       Curcio M, Vittorio O, Bell JL, Iemma F, Nicoletta FP, Cirillo G. Hyaluronic Acid within Self-Assembling Nanoparticles: Endless Possibilities for Targeted Cancer Therapy. Nanomaterials 2022;12:2851. https://doi.org/10.3390/NANO12162851.

[54].       Liu K, Huang X. Synthesis of self-assembled hyaluronan based nanoparticles and their applications in targeted imaging and therapy. Carbohydr Res 2022;511:108500. https://doi.org/10.1016/J.CARRES.2022.108500.

[55].       Alipoor R, Ayan M, Hamblin MR, Ranjbar R, Rashki S. Hyaluronic Acid-Based Nanomaterials as a New Approach to the Treatment and Prevention of Bacterial Infections. Front Bioeng Biotechnol 2022;10:913912. https://doi.org/10.3389/FBIOE.2022.913912/FULL.

[56].       Madawi EA, Al Jayoush AR, Rawas-Qalaji M, Thu HE, Khan S, Sohail M, et al. Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases. Pharmaceutics 2023;15:657. https://doi.org/10.3390/PHARMACEUTICS15020657.

[57].       Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine 2019;14:1937. https://doi.org/10.2147/IJN.S198353.

[58].       Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform—A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications. Pharmaceutics 2021;13:1291. https://doi.org/10.3390/PHARMACEUTICS13081291.

[59].       Bu X, Ji N, Dai L, Dong X, Chen M, Xiong L, et al. Self-assembled micelles based on amphiphilic biopolymers for delivery of functional ingredients. Trends Food Sci Technol 2021;114:386–98. https://doi.org/10.1016/J.TIFS.2021.06.001.

[60].       Andreana I, Bincoletto V, Ricci C, Salaroglio IC, Manzoli M, Zurletti B, et al. Smart hyaluronated micelles to enhance a gemcitabine prodrug efficacy. J Drug Deliv Sci Technol 2025;104:106518. https://doi.org/10.1016/J.JDDST.2024.106518.

[61].       Altuntaş E, Özkan B, Güngör S, Özsoy Y. Biopolymer-Based Nanogel Approach in Drug Delivery: Basic Concept and Current Developments. Pharmaceutics 2023;15:1644. https://doi.org/10.3390/PHARMACEUTICS15061644.

[62].       S F, Umashankar MS, Narayanasamy D. A Comprehensive Review of Nanogel-Based Drug Delivery Systems. Cureus 2024;16:e68633. https://doi.org/10.7759/CUREUS.68633.

[63].       Alamos-Musre S, Beltrán-Chacana D, Moyano J, Márquez-Miranda V, Duarte Y, Miranda-Rojas S, et al. From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications. Pharmaceutics 2025;17:927. https://doi.org/10.3390/PHARMACEUTICS17070927.

[64].       Fateh ST, Aghaii AH, Aminzade Z, Shahriari E, Roohpour N, Koosha F, et al. Inorganic nanoparticle-cored dendrimers for biomedical applications: A review. Heliyon 2024;10:e29726. https://doi.org/10.1016/J.HELIYON.2024.E29726.

[65].       Arpicco S, Milla P, Stella B, Dosio F. Hyaluronic Acid Conjugates as Vectors for the Active Targeting of Drugs, Genes and Nanocomposites in Cancer Treatment. Molecules 2014, Vol 19, Pages 3193-3230 2014;19:3193–230. https://doi.org/10.3390/MOLECULES19033193.

[66].       Deiss-Yehiely E, Brucks SD, Boehnke N, Pickering AJ, Kiessling LL, Hammond PT. Surface Presentation of Hyaluronic Acid Modulates Nanoparticle-Cell Association. Bioconjug Chem 2022;33:2065. https://doi.org/10.1021/ACS.BIOCONJCHEM.2C00412.

[67].       Kesharwani P, Kumar V, Goh KW, Gupta G, Alsayari A, Wahab S, et al. PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy. Molecular Cancer 2025 24:1 2025;24:205-. https://doi.org/10.1186/S12943-025-02410-X.

[68].       Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 2015;99:28. https://doi.org/10.1016/J.ADDR.2015.09.012.

[69].       Dudhwala YD, Mehta RK, Kapoor DU, Shah DP, Shah K V., Saini V. Ligand-functionalized nanocarriers for targeted breast cancer therapy: advances in receptor-mediated drug delivery. Health Nanotechnology 2026 2:1 2026;2:7-. https://doi.org/10.1186/S44301-026-00029-5.

[70].       Yan S, Na J, Liu X, Wu P. Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics 2024;16:248. https://doi.org/10.3390/PHARMACEUTICS16020248.

[71].       Ahmad Q, Mehdi S, Shaukat B, Siddique R, Asif MT, Malik A, et al. Multi-stimuli responsive nanoparticles: next-generation platforms for smart drug delivery. OpenNano 2026;29:100296. https://doi.org/10.1016/J.ONANO.2026.100296.

[72].       Zeng H, Zhang Y, Liu N, Wei Q, Yang F, Li J. Stimulus-Responsive Nanodelivery and Release Systems for Cancer Gene Therapy: Efficacy Improvement Strategies. Int J Nanomedicine 2024;19:7099. https://doi.org/10.2147/IJN.S470637.

[73].       Sied Filli M, Ibrahim AA, Aquib M, Abbas AB, Morshed A, Boakye-yiadom KO, et al. The impact of physicochemical characteristics on therapeutic efficacy of anticancer nanomaterials: a review. International Journal of Pharmaceutical Sciences and Drug Research 2019:61–70. https://doi.org/10.25004/IJPSDR.2019.110203.

[74].       Floyd TG, Gurnani P, Rho JY. Characterisation of polymeric nanoparticles for drug delivery. Nanoscale 2025;17:7738–52. https://doi.org/10.1039/D5NR00071H.

[75].       Mohd Zain H, Muhamad M, Nik Mohamed Kamal NNS. Propolis-loaded liposomes (ProLip) enhance macrophage-mediated immunomodulation and suppress breast cancer cell proliferation. Sci Rep 2025;15:35994. https://doi.org/10.1038/S41598-025-19867-X.

[76].       Chatzidaki MD, Mitsou E. Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes. Pharmaceutics 2025;17:337. https://doi.org/10.3390/PHARMACEUTICS17030337.

[77].       Rani R, Malik P, Dhania S, Mukherjee TK. Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment. Pharmaceutics 2023;15:227. https://doi.org/10.3390/PHARMACEUTICS15010227.

[78].       Daems N, Michiels C, Lucas S, Baatout S, Aerts A. Gold nanoparticles meet medical radionuclides. Nucl Med Biol 2021;100–101:61–90. https://doi.org/10.1016/J.NUCMEDBIO.2021.06.001.

[79].       Estelrich J, Escribano E, Queralt J, Busquets MA. Iron Oxide Nanoparticles for Magnetically-Guided and Magnetically-Responsive Drug Delivery. Int J Mol Sci 2015;16:8070. https://doi.org/10.3390/IJMS16048070.

[80].       Speranza G. Carbon Nanomaterials: Synthesis, Functionalization and Sensing Applications. Nanomaterials 2021, Vol 11, Page 967 2021;11:967. https://doi.org/10.3390/NANO11040967.

[81].       Wang L, Zhu SJ, Wang HY, Qu SN, Zhang YL, Zhang JH, et al. Common origin of green luminescence in carbon nanodots and graphene quantum dots. ACS Nano 2014;8:2541–7. https://doi.org/10.1021/NN500368M.

[82].       Teixeira S, Ferreira D, Rodrigues LR, Carvalho MA, Castanheira EMS. Albumin/Hyaluronic Acid Gel Nanoparticles Loaded with a Pyrimidine-Based Drug for Potent Anticancer Activity. Gels 2025;11:759. https://doi.org/10.3390/GELS11090759/S1.

[83].       Juretić D. Designed Multifunctional Peptides for Intracellular Targets. Antibiotics 2022;11:1196. https://doi.org/10.3390/ANTIBIOTICS11091196.

[84].       Deng S, Gigliobianco MR, Censi R, Di Martino P. Polymeric Nanocapsules as Nanotechnological Alternative for Drug Delivery System: Current Status, Challenges and Opportunities. Nanomaterials 2020, Vol 10, Page 847 2020;10:847. https://doi.org/10.3390/NANO10050847.

[85].       Medina MA, Oza G, Sharma A, Arriaga LG, Hernández JMH, Rotello VM, et al. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health 2020;17:2078. https://doi.org/10.3390/IJERPH17062078.

[86].       Bhadran A, Polara H, Babanyinah GK, Baburaj S, Stefan MC. Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery. Cancers (Basel) 2025;17:2303. https://doi.org/10.3390/CANCERS17142303.

[87].       Haddad R, Alrabadi N, Altaani B, Li T. Paclitaxel Drug Delivery Systems: Focus on Nanocrystals’ Surface Modifications. Polymers (Basel) 2022;14:658. https://doi.org/10.3390/POLYM14040658.

[88].       Postigo-Corrales F, Beltrán-Videla A, Lázaro-Sánchez AD, Hurtado AM, Conesa-Zamora P, Arroyo AB, et al. Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions. Int J Mol Sci 2025;26:7119. https://doi.org/10.3390/IJMS26157119.

[89].       Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364. https://doi.org/10.1016/J.EJPHAR.2014.07.025.

[90].       Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene 2024;44:193. https://doi.org/10.1038/S41388-024-03227-6.

[91].       Li H, Prever L, Hirsch E, Gulluni F. Targeting pi3k/akt/mtor signaling pathway in breast cancer. Cancers (Basel) 2021;13:3517. https://doi.org/10.3390/CANCERS13143517/S1.

[92].       Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res 2016;6:1609.

[93].       Wang M, Liu H, Huang J, Cai T, Xu ZP, Zhang L. Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems. J Nanobiotechnology 2025;23:362. https://doi.org/10.1186/S12951-025-03433-8.

[94].       Berikkhanova K, Inuwa I, Jibo AG, Berikkhanov N, Bikhanov N, Sultan Y, et al. Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy. Int J Mol Sci 2025;27:248. https://doi.org/10.3390/IJMS27010248.

[95].       [95]      Sheikh M, Khobragade D, Sakore A, Telrandhe U. Harnessing albumin’s natural tumor-targeting properties: nanoplatform strategies for triple-negative breast cancer therapy. Discover Nano 2025 21:1 2026;21:3-. https://doi.org/10.1186/S11671-025-04411-7.

[96].       Fahmy SA, Sedky NK, Hassan HAFM, Abdel-Kader NM, Mahdy NK, Amin MU, et al. Synergistic Enhancement of Carboplatin Efficacy through pH-Sensitive Nanoparticles Formulated Using Naturally Derived Boswellia Extract for Colorectal Cancer Therapy. Pharmaceutics 2024;16:1282. https://doi.org/10.3390/PHARMACEUTICS16101282/S1.

[97].       Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM. Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review. Int J Mol Sci 2021;22:10319. https://doi.org/10.3390/IJMS221910319.

[98].       Sendur MAN, Hizal M, Çakar B, Aktepe OH, Eraslan E, Arık Z, et al. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program. BMC Cancer 2025;25:1897. https://doi.org/10.1186/S12885-025-15287-2.

[99].       Yuan Y, Long H, Zhou Z, Fu Y, Jiang B. PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. Biomolecules 2023;13:93. https://doi.org/10.3390/BIOM13010093.

[100].    Orcutt KP, Parsons AD, Sibenaller ZA, Scarbrough PM, Zhu Y, Sobhakumari A, et al. Erlotinib-mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4. Cancer Res 2011;71:3932. https://doi.org/10.1158/0008-5472.CAN-10-3425.

[101].    Guo H, Zhang X, Xie S, Chen T, Xie D, Cai Y, et al. Gefitinib enhances the anti-tumor immune response against EGFR-mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H. Int J Oncol 2022;61:146. https://doi.org/10.3892/IJO.2022.5436.

[102].    Babu A, Muralidharan R, Amreddy N, Mehta M, Munshi A, Ramesh R. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy. IEEE Trans Nanobioscience 2016;15:849. https://doi.org/10.1109/TNB.2016.2621730.

[103].    Li W, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, et al. MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic. Front Cell Dev Biol 2021;9:640587. https://doi.org/10.3389/FCELL.2021.640587/FUL

[104].    Liu PL, Liu WL, Chang JM, Chen YH, Liu YP, Kuo HF, et al. MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. PLoS One 2017;12:e0180844. https://doi.org/10.1371/JOURNAL.PONE.0180844.

[105].    Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, et al. Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics 2022;14:2682. https://doi.org/10.3390/PHARMACEUTICS14122682.

[106].    Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, et al. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci 2020;263:118525. https://doi.org/10.1016/J.LFS.2020.118525.

[107].    Guo LM, Ding GF, Xu WC, Ge H, Jiang Y, Lu YF. Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy. Oxid Med Cell Longev 2022;2022. https://doi.org/10.1155/2022/5938688.

[108].    Chen P, Yang W, Nagaoka K, Huang G Lo, Miyazaki T, Hong T, et al. An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors. Advanced Science 2023;10:2205139. https://doi.org/10.1002/ADVS.202205139;WGROUP:STRING:PUBLICATION.

[109].    Wu QJ, Lv WL. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective. IET Nanobiotechnol 2024;2024:5593879. https://doi.org/10.1049/2024/5593879.

[110].    Butowska K, Han X, Gong N, El-Mayta R, Haley RM, Xue L, et al. Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy. Acta Pharm Sin B 2022;13:1429. https://doi.org/10.1016/J.APSB.2022.07.011.

[111].    Qureshi MJ, Narde GK, Ahuja A, Meenakshi DU, Al Balushi K. Combination Therapy Using Phytochemicals and PARP Inhibitors in Hybrid Nanocarriers: An Optimistic Approach for the Management of Colon Cancer. Int J Mol Sci 2025;26:7350. https://doi.org/10.3390/IJMS26157350.

[112].    Nabil G, Alzhrani R, Alsaab HO, Atef M, Sau S, Iyer AK, et al. CD44 Targeted Nanomaterials for Treatment of Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:898. https://doi.org/10.3390/CANCERS13040898.

[113].    Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J Drug Target 2015;23:605–18. https://doi.org/10.3109/1061186X.2015.1052072.

[114].    Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015;33:941–51. https://doi.org/10.1038/NBT.3330.

[115].    Roszkowski S, Durczyńska Z, Szablewska S. Targeted nanodelivery systems for personalized cancer therapy. Reports of Practical Oncology and Radiotherapy 2025;29:776. https://doi.org/10.5603/RPOR.103524.

[116].    Lee KL, Kuo YC, Ho YS, Huang YH. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers 2019, Vol 11, Page 1334 2019;11:1334. https://doi.org/10.3390/CANCERS11091334.

[117].    Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, van Reesema LLS, et al. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel) 2020;12:2392. https://doi.org/10.3390/CANCERS12092392.

[118].    Lee JJ, Ng KY, Bakhtiar A. Extracellular matrix: unlocking new avenues in cancer treatment. Biomark Res 2025;13:78. https://doi.org/10.1186/S40364-025-00757-3.

[119].    Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduction and Targeted Therapy 2024 9:1 2024;9:200-. https://doi.org/10.1038/s41392-024-01889-y.

[120].    Battogtokh G, Akala EO. Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment. Pharmaceutics 2025;17:425. https://doi.org/10.3390/PHARMACEUTICS17040425/S1.

[121].    Anderson NM, Simon MC. The tumor microenvironment. Current Biology 2020;30:R921–5. https://doi.org/10.1016/J.CUB.2020.06.081.

[122].    Tsang JY, Tse GM. Update on triple-negative breast cancers – highlighting subtyping update and treatment implication. Histopathology 2023;82:17–35. https://doi.org/10.1111/his.14784.

[123].    Prakash J, Shaked Y. The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics. Cancer Discov 2024;14:1375–88. https://doi.org/10.1158/2159-8290.cd-24-0002.

[124].    Qi H, Li Y, Geng Y, Wan X, Cai X. Nanoparticle-mediated immunogenic cell death for cancer immunotherapy. Int J Pharm 2024;656:124045. https://doi.org/10.1016/J.IJPHARM.2024.124045.

[125].    Soares FA, Salinas B, Reis S, Nunes C. Hyaluronic acid-engineered milk extracellular vesicles to target triple negative breast cancer through CD44. Pharm Biol 2025;63:411. https://doi.org/10.1080/13880209.2025.2511807.

[126].    Agelopoulos K, Greve B, Schmidt H, Pospisil H, Kurtz S, Bartkowiak K, et al. Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468. BMC Cancer 2010;10:78. https://doi.org/10.1186/1471-2407-10-78.

[127].    Grant C V., Carver CM, Hastings SD, Ramachandran K, Muniswamy M, Risinger AL, et al. Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype. Breast Cancer Res Treat 2019;177:345. https://doi.org/10.1007/S10549-019-05324-7.

[128].    Jogalekar MP, Serrano EE. Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments. PeerJ 2018;2018:e4340. https://doi.org/10.7717/PEERJ.4340/SUPP-2.

[129].    Pawar A, Prabhu P. Nanosoldiers: A promising strategy to combat triple negative breast cancer. Biomedicine & Pharmacotherapy 2019;110:319–41. https://doi.org/10.1016/J.BIOPHA.2018.11.122.

[130].    Ridnour A, Cheng RYS, Patel NL, Back T, Basudhar D, Somasundaram V, et al. Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model. J Vis Exp 2020;2020:10.3791/60316. https://doi.org/10.3791/60316.

[131].    Janitri V, ArulJothi KN, Ravi Mythili VM, Singh SK, Prasher P, Gupta G, et al. The roles of patient‐derived xenograft models and artificial intelligence toward precision medicine. MedComm (Beijing) 2024;5:e745. https://doi.org/10.1002/MCO2.745.

[132].    Kurakula H, Vaishnavi S, Sharif MY, Ellipilli S. Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases. ACS Omega 2023;8:20234–50. https://doi.org/10.1021/acsomega.3c01703.

[133].    Ridnour A, Cheng RYS, Patel NL, Back T, Basudhar D, Somasundaram V, et al. Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model. J Vis Exp 2020;2020:10.3791/60316. https://doi.org/10.3791/60316.

[134].    Siafaka PI, Üstündağ Okur N, Karavas E, Bikiaris DN. Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses. Int J Mol Sci 2016;17:1440. https://doi.org/10.3390/IJMS17091440.

[135].    Parvin N, Aslam M, Alam MN, Mandal TK. Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration. Nanomaterials 2025, Vol 15, Page 1733 2025;15:1733. https://doi.org/10.3390/NANO15221733.

[136].    Tripodo G, Trapani A, Torre ML, Giammona G, Trapani G, Mandracchia D. Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and challenges. European Journal of Pharmaceutics and Biopharmaceutics 2015;97:400–16. https://doi.org/10.1016/J.EJPB.2015.03.032.

[137].    Wang L, Zhou F, Xie W. Advances in hyaluronic acid-based biomaterials: applications in cancer therapy, wound healing, and disease management. J Mater Sci Mater Med 2025;36:91-. https://doi.org/10.1007/S10856-025-06946-8/FIGURES/23.

[138].    Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biol Ther 2018;19:858. https://doi.org/10.1080/15384047.2018.1456599.

[139].    Bhat V, Piaseczny M, Goodale D, Patel U, Sadri A, Allan AL. Lung-derived soluble factors support stemness/plasticity and metastatic behaviour of breast cancer cells via the FGF2-DACH1 axis. Clinical & Experimental Metastasis 2024 41:5 2024;41:717–31. https://doi.org/10.1007/S10585-024-10284-4.

[140].    Yang H, Zhao Y, Wang Y, Ma X, Ling J, Zeng X, et al. Triple-Negative Breast Cancer Brain Metastasis: A Comprehensive Review of Epidemiology, Molecular Pathobiology, and Therapeutic Frontiers. Cancers (Basel) 2026;18:1179. https://doi.org/10.3390/CANCERS18071179.

[141].    Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008;34:592. https://doi.org/10.1016/J.CTRV.2008.04.003.

[142].    Xiang S, Zhan H, Zhan J, Li X, Lin X, Sun W. Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced T cell-mediated tumor immunotherapy. Int J Pharm X 2025;10:100400. https://doi.org/10.1016/J.IJPX.2025.100400.

[143].    Bai R, Li Y, Jian L, Yang Y, Zhao L, Wei M. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol Cancer 2022;21. https://doi.org/10.1186/S12943-022-01645-2.

[144].    Yang C, He Y, Zhang H, Liu Y, Wang W, Du Y, et al. Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo. Oncotarget 2015;6:15283. https://doi.org/10.18632/ONCOTARGET.3681.

[145].    Paliwal R, Babu RJ, Palakurthi S. Nanomedicine Scale-up Technologies: Feasibilities and Challenges. AAPS PharmSciTech 2014;15:1527. https://doi.org/10.1208/S12249-014-0177-9.

[146].    Stucchi F, Li M, Castellano G, Cellesi F. Regulatory framework for polymer-based nanotherapeutics in clinical translation. Front Bioeng Biotechnol 2026;14:1735885. https://doi.org/10.3389/FBIOE.2026.1735885/FULL.

[147].    Desai N, Rana D, Patel M, Bajwa N, Prasad R, Vora LK. Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. Small 2025;21:2502315. https://doi.org/10.1002/SMLL.202502315.

[148].    Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, et al. CD44 Isoform status predicts response to treatment with Anti-CD44 antibody in cancer patients. Clinical Cancer Research 2015;21:2753–62. https://doi.org/10.1158/1078-0432.CCR-14-2141.

[149].    Fernández-Tabanera E, Melero-Fernández de Mera RM, Alonso J. CD44 In Sarcomas: A Comprehensive Review and Future Perspectives. Front Oncol 2022;12:909450. https://doi.org/10.3389/FONC.2022.909450/FULL.

[150].    Luo Z, Dai Y, Gao H. Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B 2019;9:1099–112. https://doi.org/10.1016/J.APSB.2019.06.004.

[151].    Batool S, Sohail S, ud Din F, Alamri AH, Alqahtani AS, Alshahrani MA, et al. A detailed insight of the tumor targeting using nanocarrier drug delivery system. Drug Deliv 2023;30:2183815. https://doi.org/10.1080/10717544.2023.2183815.

[152].    Umar AK, Limpikirati PK, Rivai B, Ardiansah I, Sriwidodo S, Luckanagul JA. Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing. Heliyon 2025;11:e41246. https://doi.org/10.1016/J.HELIYON.2024.E41246.

[153].    Kantesaria R, Panda HS. A Review on AI-Based Data-Driven Models for Optimization of Nanocarriers as Drug Delivery Systems. ACS Biomater Sci Eng 2026;12:1397–418. https://doi.org/10.1021/ACSBIOMATERIALS.5C01998.

[154].    Sharon S, Mainkar G, Zangi L. Personalized Nanomedicine: Integrating Molecular Stratification with Engineered Delivery Systems. Journal of Nanotheranostics 2026, Vol 7, Page 9 2026;7:9. https://doi.org/10.3390/JNT7020009.